Invenomic Capital Management’s Coursera COUR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.8M Sell
2,798,362
-752,364
-21% -$4.27M 0.94% 39
2026
Q1
$20.7M Buy
3,550,726
+2,644,502
+292% +$16.5M 0.95% 38
2025
Q4
$6.67M Buy
906,224
+611,325
+207% +$5.32M 0.31% 96
2025
Q3
$3.45M Sell
294,899
-991,934
-77% -$10.8M 0.17% 117
2025
Q2
$11.3M Sell
1,286,833
-793,813
-38% -$6.5M 0.64% 59
2025
Q1
$13.9M Sell
2,080,646
-236,067
-10% -$1.87M 0.7% 52
2024
Q4
$19.7M Sell
2,316,713
-373,650
-14% -$2.89M 0.94% 27
2024
Q3
$21.4M Buy
2,690,363
+172,585
+7% +$1.36M 1.17% 31
2024
Q2
$18M Buy
+2,517,778
New +$23.9M 0.88% 38
2023
Q3
Sell
-1,934,393
Closed -$25.2M 151
2023
Q2
$25.2M Buy
1,934,393
+1,695,383
+709% +$20.3M 1.28% 23
2023
Q1
$2.75M Buy
+239,010
New +$3.09M 0.16% 114
2022
Q2
Sell
-127,826
Closed -$2.94M 154
2022
Q1
$2.94M Buy
+127,826
New +$2.62M 0.31% 83

Other funds holding COUR

Invenomic Capital Management's COUR Position: Q2 2026 in Review

Invenomic Capital Management reduced its Coursera (COUR) stake by 21% in Q2 2026, selling an estimated $4.27M and leaving 2,798,362 shares worth $15.8M. The position accounts for 0.94% of the portfolio, ranked #39.

Invenomic Capital Management first reported a position in COUR in Q1 2022 and has held it in 12 quarters since. The position peaked at $25.2M in Q2 2023. 249 funds tracked by Wall St. Rank hold COUR as of Q2 2026.

  • Invenomic Capital Management held 2,798,362 shares of Coursera worth $15.8M as of Q2 2026.
  • Invenomic Capital Management sold 752,364 Coursera shares in Q2 2026, an estimated $4.27M.
  • Coursera made up 0.94% of Invenomic Capital Management's portfolio in Q2 2026, its #39 holding.
  • Invenomic Capital Management first reported a position in Coursera in Q1 2022 and has held it in 12 quarters since.
  • Invenomic Capital Management's Coursera position peaked at $25.2M in Q2 2023.
  • 249 funds tracked by Wall St. Rank held Coursera as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.